Google settles pharmacy ad probe for $500 million

Advertisement
By Associated Press | Updated: 7 June 2012 17:18 IST
Highlights
  • Google Inc. has agreed to pay $500 million to settle a federal investigation into the Internet search leader's distribution of online ads from Canadian pharmacies that were illegally selling prescription and non-prescription drugs to American consumers.
Google Inc. has agreed to pay $500 million to settle a U.S. government investigation into the Internet search leader's distribution of online ads from Canadian pharmacies illegally selling prescription and non-prescription drugs to American consumers, a U.S. attorney in Rhode Island said on Wednesday.

The settlement means the Internet search leader will not face criminal prosecution for accusations that it improperly profited from ads promoting Canadian pharmacies that illegally imported drugs into the United States, U.S. Attorney Peter F. Neronha said.

The $500 million represents the gross revenues Google collected in ad buys from the Canadian pharmacies, plus the earnings generated from the illegal sales of drugs to American consumers, federal investigators said.

Federal officials also say Google knew as early as 2003 that its ad system was allowing Canadian pharmacies to make illegal sales. These transactions included the sale of prescription drugs without prescriptions from a licensed medical practitioner, federal prosecutors said.

Shipping prescription drugs into the U.S. from abroad violates drug and other laws, investigators said. Prescription drugs shipped into the U.S. from Canada are not subject to oversight by Canadian regulatory authorities and many sell drugs from countries with inadequate pharmacy regulations, prosecutors said.

The investigation laid bare how vulnerable the company's automated ad system known as AdWords is to the machinations of shady operators. The ad network is a major money maker for Google and is expected to generate more than $30 billion in revenue this year.

Google acknowledged holes in its ad system in a federal lawsuit filed last fall against dozens of "rogue" online pharmacies that were finding ways to place ads for drugs despite the company's efforts to prevent abuses. The individuals identified in the complaint were in New York, Tennessee and Ohio.

In one of the more common practices, the illicit drug dealers would plug subtle misspellings of drug names frequently entered into Google's search engine to generate ads alongside the results. For instance, one illegal drug advertiser spelled the anabolic steroid Dianabol as "Diano bol" in Google's automated system to produce an ad, according to the lawsuit in San Jose federal court.

Google has obtained court orders banning some of the rogue pharmacies named in the lawsuit and is still seeking injunctions against the others.

Rhode Island has aggressively investigated doping activities recently. Last year, the Chinese company GeneScience Pharmaceutical Co. and its CEO pleaded guilty to selling human growth hormone and agreed to pay $7.5 million.

The Google lawsuit came seven months after the Internet search leader imposed new restrictions on the kinds of pharmaceutical ads it would accept in the U.S. and Canada. The new rules were supposed to allows ads only from U.S. pharmacies that had been accredited by a special program run by the National Association Boards of Pharmacy. In Canada, the accreditation had to come from the Canadian International Pharmacy Association.

Google's critics have complained in the past that the company and other websites haven't been vigilant about policing pharmaceutical ads because they are so lucrative. Drug and health care advertising generated about $1 billion in Internet spending last year and is expected to grow to nearly $1.9 billion by 2015, according to the research firm eMarketer Inc.

The agreement also ends speculation that began in May when the company made a reference in its quarterly filing with the Securities and Exchange Commission to a Justice Department investigation into the usage of Google's automated system for placing ads alongside search results and other content at hundreds of thousands of websites. Google had raised even more intrigue by subtracting $500 million from its first-quarter earnings to cover a potential settlement.

For the latest tech news and reviews, follow Gadgets 360 on X, Facebook, WhatsApp, Threads and Google News. For the latest videos on gadgets and tech, subscribe to our YouTube channel. If you want to know everything about top influencers, follow our in-house Who'sThat360 on Instagram and YouTube.

Advertisement
Popular Mobile Brands
  1. Moto Book 60 Pro With Up to Intel Core Ultra 7 CPU Launched in India
  2. Amazon Great Indian Festival 2025: Smartphone Deals Teased Ahead of Sale
  3. Nothing Ear 3 Teaser Drops Ahead of Imminent Launch
  4. IFA 2025: Motorola Edge 60 Neo Unveiled Alongside Moto G06, Moto G06 Power
  5. WhatsApp Could Implement iOS 26's Liquid Glass Across its iPhone App
  6. Amazon Great Indian Festival Sale 2025: Deals on Laptops, Tablets Teased
  7. OnePlus 15 Will Swap Hasselblad-Tuned Cameras for This New Image Engine
  1. NASA and NOAA Set to Launch Solar Probes for Space Weather Forecasting
  2. Qualcomm Partners BMW to Bring New Automated Driving System to BMW iX3 SUV
  3. James Webb Spots Bizarre Planet-Forming Disk Full of Carbon Dioxide
  4. IFA 2025: Lenovo Legion Pro 7 (2025) With Nvidia RTX 5080 GPU Unveiled Alongside ThinkBook VertiFlex Concept
  5. Google Reportedly Lists New Outdoor and Indoor Nest Cam Models Alongside Nest Doorbell in Google Home App
  6. Samsung Galaxy Tab S11, Galaxy Tab S11 Ultra Price in India Announced; Pre-Orders Open Ahead of Sale
  7. Nubia Air Launched at IFA 2025 With Sleek 5.9mm Profile and 5,000mAh Battery: Price, Specifications
  8. Facebook Is Trying to Bring Back Pokes Playing on the 2010s Nostalgia
  9. NFT Trading Rose to New High in August Even as Sales Dipped: Report
  10. Nothing Ear 3 Teaser Drops Ahead of Imminent Launch
Gadgets 360 is available in
Download Our Apps
Available in Hindi
© Copyright Red Pixels Ventures Limited 2025. All rights reserved.